Table 1.
Comparison of demographic and clinical findings in the treatment of moderate persistent asthma by propolis and placebo tablet
| Total | Before trial | After trial | |||
|---|---|---|---|---|---|
| Propolis | Placebo | Propolis | Placebo | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Cough | 50 (96%) | 25 (96%) | 25 (96%) | 7 (27%)*† | 23 (88%) |
| Dyspnea | 52 (100%) | 26 (100%) | 26 (100%) | 10 (38%)*† | 24 (94%) |
| Wheeze | 52 (100%) | 26 (100%) | 26 (100%) | 11 (42%)*† | 24 (94%) |
| Sputum | 42 (81%) | 23 (88.5%) | 19 (70%) | 21 (80%) | 23 (88%) |
| Nocturnal Symptoms | 35 (67%) | 20 (77%) | 15 (58%) | 5 (19%)*† | 21 (82%)‡ |
| Acute attack | 13 (25%) | 7 (27%) | 4 (15%) | 0 (0%)*† | 4 (22%) |
| AHR | 45 (86%) | 22 (85%) | 23 (88%) | 13 (50%)*† | 24 (94%) |
| GERD | 24 (46%) | 12 (46%) | 12 (46%) | 8 (31%) | 14 (54%) |
| PND | 29 (56%) | 14 (56%) | 15 (58%) | 13 (50%) | 17 (65%) |
AHR=Airway hyper-responsiveness, GERD=Gastero-esophageal reflux, PND=Post- nasal drip
**p<0.05, **p<0.01, ***p<0.01=Significant difference between before and after the trial (McNemar test)
†=Significant difference between propolis and the placebo after the trial (chi square test)
‡=Significant difference between before and after the trial in the placebo group (McNemar test)